Introduction

Chronic Nausea Vomiting Syndrome (CNVS) is a functional gastroduodenal disorder defined by the Rome IV classification system. It is characterized by bothersome nausea occurring at least one day per week and/or one or more vomiting episodes per week, in the absence of an identifiable organic, systemic, or metabolic cause. CNVS represents an important consolidation in the Rome IV framework: it unifies two previously separate Rome III entities, chronic idiopathic nausea (CIN) and functional vomiting (FV), into a single diagnostic category. This merger reflects the clinical observation that nausea and vomiting frequently coexist along a spectrum, and that separating them into distinct diagnoses often fails to capture the real-world presentation of patients who experience both symptoms in varying proportions.

The recognition of CNVS as a distinct entity is clinically significant because chronic nausea and vomiting are among the most common reasons for gastroenterology consultation. When routine investigations fail to reveal a structural, biochemical, or motility-related explanation, many patients are left without a clear diagnosis and may undergo repeated, unnecessary testing. The Rome IV criteria for CNVS provide a positive diagnostic framework that enables clinicians to identify the condition based on defined symptom patterns and appropriate exclusions, rather than relying solely on the absence of organic findings.

Historical Context and Evolution of the Diagnostic Criteria

The Rome classification system has addressed nausea and vomiting disorders since its early iterations, but the approach to chronic, unexplained nausea and vomiting has evolved considerably over time.

In Rome III (2006), the functional gastroduodenal disorders included two separate entities for patients with chronic nausea or vomiting without an organic cause:

• Chronic idiopathic nausea (CIN): Defined as bothersome nausea occurring several times per week, usually not associated with vomiting, in the absence of an identifiable cause. The key feature was the predominance of nausea over vomiting.
• Functional vomiting (FV): Defined as one or more episodes of vomiting per week, in the absence of an eating disorder, rumination, or major psychiatric disease, with no evidence of self-induced vomiting, organic disease, or central nervous system abnormality. Here, the defining feature was recurrent vomiting, which could occur with or without nausea.

In clinical practice, the rigid separation of CIN and FV proved problematic. Many patients presented with both significant nausea and recurrent vomiting, and the distinction between "nausea-predominant" and "vomiting-predominant" phenotypes was often arbitrary. Moreover, the same patient could transition between predominant nausea and predominant vomiting over time, making classification unstable.

The Rome IV committee, in its 2016 revision, addressed this by merging CIN and FV into a single entity: Chronic Nausea Vomiting Syndrome (CNVS). The new criteria use an inclusive "and/or" construction for the symptom threshold (nausea at least 1 day per week and/or vomiting at least 1 episode per week), allowing the diagnosis to capture the full spectrum of patients. Rome IV also refined the exclusion criteria, explicitly requiring that self-induced vomiting, eating disorders, regurgitation, and rumination be excluded, and mandating that routine investigations including upper endoscopy have not revealed an organic cause.

The temporal requirement was also standardized: criteria must be fulfilled for the last 3 months, with symptom onset at least 6 months before the time of diagnosis. This dual duration criterion (active symptoms for 3 months; total symptom duration of at least 6 months) is consistent with the approach used for other Rome IV gastroduodenal disorders and helps to exclude transient or self-limited causes of nausea and vomiting.

Epidemiology

Estimating the prevalence of CNVS is challenging because the diagnosis is relatively new as a unified entity, and much of the epidemiologic data on chronic unexplained nausea and vomiting predates the Rome IV framework.

Population-based studies using Rome III criteria reported prevalence rates for chronic idiopathic nausea in the range of 0.6% to 2.5% and for functional vomiting in the range of 0.2% to 1.5% in the general adult population. Because CNVS encompasses both of these categories and captures overlap cases that previously fell between them, the combined prevalence under Rome IV criteria is expected to be higher, likely in the range of 2% to 5% depending on the population surveyed and the methodology used.

Several demographic and clinical patterns have been observed:

• Sex distribution: CNVS is significantly more common in women than in men, with female-to-male ratios in the range of 2:1 to 4:1 reported in clinic-based series. This female predominance mirrors the sex distribution of other functional gastrointestinal disorders, including functional dyspepsia and irritable bowel syndrome.
• Age of onset: CNVS can present at any age, but the peak onset is in early to middle adulthood (ages 20 to 50). Adolescents and young adults represent a significant proportion of cases in some series.
• Comorbidities: Patients with CNVS frequently report overlapping functional GI disorders (functional dyspepsia, irritable bowel syndrome, functional heartburn) as well as extraintestinal functional somatic syndromes (fibromyalgia, chronic fatigue, chronic headache). Psychiatric comorbidity is common, with anxiety disorders and depression reported in 40% to 60% of CNVS patients in referral populations.
• Healthcare utilization: Chronic nausea and vomiting are associated with high healthcare utilization, including repeated emergency department visits, hospitalizations, specialist consultations, and diagnostic procedures. Patients with undiagnosed CNVS may undergo multiple upper endoscopies, gastric emptying studies, CT scans, and laboratory panels before the functional nature of their condition is recognized.

Pathophysiology

The pathophysiology of CNVS is multifactorial and incompletely understood. As with other functional gastrointestinal disorders, the current conceptual model centers on disordered brain-gut interaction, in which alterations in peripheral gut physiology, central nervous system processing, and psychosocial factors converge to produce symptoms in the absence of identifiable structural pathology.

Central Mechanisms

Nausea is a subjective, conscious experience generated by the central nervous system. The neural circuitry underlying nausea involves a complex network of brainstem nuclei (particularly the nucleus tractus solitarius and the area postrema), the vestibular system, higher cortical areas (including the insular cortex and the anterior cingulate cortex), and descending modulatory pathways. In CNVS, it is hypothesized that heightened sensitivity or abnormal processing within these central nausea pathways produces the sensation of nausea in the absence of the peripheral stimuli that normally trigger it.

Functional neuroimaging studies have demonstrated altered activation patterns in the insular cortex, prefrontal cortex, and amygdala in patients with chronic functional nausea, suggesting that both sensory processing and emotional modulation of nausea are disrupted. These findings parallel observations in other functional GI disorders and in chronic pain conditions, where central sensitization plays a prominent role.

Peripheral Mechanisms

Although CNVS is by definition a disorder without identifiable organic pathology, subtle peripheral abnormalities may contribute to symptom generation:

• Gastric motor dysfunction: Some patients with CNVS demonstrate impaired gastric accommodation (the reflex relaxation of the gastric fundus in response to food intake) or mild delays in gastric emptying that do not meet the threshold for a diagnosis of gastroparesis. These subclinical motor abnormalities may generate signals that are amplified by central sensitization.
• Visceral hypersensitivity: Enhanced sensitivity to gastric distension and to chemical stimulation of the upper GI tract has been documented in patients with chronic nausea. Barostat studies have shown reduced thresholds for discomfort during balloon distension of the stomach in some CNVS patients.
• Duodenal eosinophilia and low-grade inflammation: Emerging research has identified increased eosinophil and mast cell counts in the duodenal mucosa of some patients with functional dyspepsia and overlapping nausea syndromes. These findings suggest that subtle immune activation at the mucosal level may play a role in symptom generation, possibly through local neural sensitization.
• Autonomic dysfunction: Abnormalities in autonomic nervous system function, including reduced heart rate variability and impaired sympathovagal balance, have been observed in subsets of CNVS patients, particularly those with concurrent postural symptoms or fatigue.

Psychosocial and Behavioral Factors

Psychological distress is both a risk factor for and a consequence of CNVS. Anxiety, depression, somatization, and a history of adverse life events are overrepresented in CNVS populations. The relationship is bidirectional: chronic nausea and vomiting impair quality of life, social functioning, and occupational performance, which in turn exacerbate psychological distress and perpetuate symptoms through heightened vigilance, anticipatory nausea, and maladaptive coping behaviors (such as dietary restriction and social avoidance).

The concept of learned nausea, analogous to anticipatory nausea in chemotherapy patients, is relevant to CNVS. When nausea is repeatedly paired with certain environmental cues (eating, specific foods, social situations), a conditioned response may develop such that the cue itself triggers nausea, independent of any peripheral stimulus. This conditioning mechanism can be difficult to extinguish without targeted behavioral intervention.

The Rome IV Diagnostic Criteria: Detailed Breakdown

The Rome IV diagnostic criteria for CNVS require that all of the following be present for the last 3 months, with symptom onset at least 6 months before diagnosis:

Criterion 1: Bothersome Nausea Occurring at Least 1 Day Per Week and/or One or More Vomiting Episodes Per Week

This criterion establishes the minimum symptom frequency and severity required for the diagnosis. Two key elements are embedded within it:

• "Bothersome" nausea: The nausea must be severe enough to be considered bothersome by the patient, meaning it interferes with daily activities, quality of life, or psychosocial functioning. Mild, transient nausea that does not affect function does not meet this threshold. The term "bothersome" is inherently subjective, and clinicians should use patient-reported impact on daily life as the gauge.
• Frequency threshold: Nausea must occur on at least 1 day per week, and/or the patient must experience at least 1 vomiting episode per week. The "and/or" construction is critical: a patient who experiences bothersome nausea 3 days per week without ever vomiting qualifies, a patient who vomits twice per week without significant nausea between episodes qualifies, and a patient with both frequent nausea and weekly vomiting qualifies. This inclusive design captures the full clinical spectrum.

In clinical practice, it is helpful to ask patients to keep a symptom diary for 2 to 4 weeks, documenting the days on which nausea occurs, its severity (using a numeric rating scale or visual analog scale), and the frequency of vomiting episodes. This provides objective documentation of whether the frequency threshold is met.

Criterion 2: Self-Induced Vomiting, Eating Disorders, Regurgitation, and Rumination Are Excluded

This exclusion criterion is essential for distinguishing CNVS from conditions in which nausea and vomiting are secondary to a behavioral or functional disorder with a different pathophysiologic mechanism and treatment approach:

• Self-induced vomiting: The clinician must establish that the vomiting is not voluntarily or deliberately induced by the patient. Self-induced vomiting is most commonly associated with eating disorders (see below) but may also occur in other psychiatric contexts.
• Eating disorders: Bulimia nervosa, anorexia nervosa (purging subtype), and other specified feeding or eating disorders (OSFED) must be excluded. Patients with eating disorders may present with frequent vomiting, but the vomiting occurs in the context of body image disturbance, compensatory behaviors, and disordered eating patterns. Screening instruments such as the SCOFF questionnaire or the Eating Disorder Examination Questionnaire (EDE-Q) can assist in identifying eating disorders, and referral for formal psychiatric or psychological evaluation may be warranted when clinical suspicion exists.
• Regurgitation: Effortless return of gastric contents to the mouth without the preceding nausea and retching that characterize vomiting. Regurgitation is the hallmark of gastroesophageal reflux and, when isolated, is classified under GERD or functional heartburn rather than CNVS.
• Rumination: The repeated, effortless regurgitation and rechewing or expulsion of recently ingested food, as defined by the Rome IV criteria for rumination syndrome. Rumination is a distinct behavioral entity with a different pathophysiology and treatment approach (primarily diaphragmatic breathing retraining).

It is important to note that this criterion requires active clinical exclusion, not merely the absence of a spontaneous disclosure. Patients may be reluctant to volunteer information about self-induced vomiting or disordered eating behaviors, and the clinician should ask directly and non-judgmentally about these issues.

Criterion 3: No Evidence of Organic, Systemic, or Metabolic Disease Likely to Explain Symptoms on Routine Investigations (Including at Upper Endoscopy)

This criterion mandates that a reasonable diagnostic evaluation has been performed to exclude organic, systemic, and metabolic causes of chronic nausea and vomiting. The Rome IV criteria explicitly require that the workup include upper endoscopy (esophagogastroduodenoscopy, EGD), reflecting the committee's view that structural exclusion of the upper GI tract is a necessary component of the diagnostic evaluation for CNVS.

The scope of "routine investigations" is intentionally left somewhat flexible, as the appropriate workup depends on the clinical context, the patient's age, comorbidities, and the specific features of the presentation. However, a reasonable baseline evaluation for suspected CNVS typically includes:

• Laboratory studies: Complete blood count, comprehensive metabolic panel (including hepatic and renal function, electrolytes, glucose), thyroid function tests, lipase, and, in women of reproductive age, a pregnancy test. Additional testing (e.g., cortisol, calcium, celiac serologies, inflammatory markers) may be guided by clinical suspicion.
• Upper endoscopy (EGD): To exclude peptic ulcer disease, erosive esophagitis, eosinophilic esophagitis, gastric outlet obstruction, mass lesions, and other mucosal pathology. Biopsies should be obtained per standard protocol, including duodenal biopsies if celiac disease or eosinophilic duodenitis is in the differential.
• Abdominal imaging: Depending on the clinical picture, abdominal ultrasound or CT may be performed to evaluate for biliary disease, pancreatic pathology, or anatomical abnormalities (e.g., SMA syndrome, malrotation).
• Gastric emptying study: A 4-hour solid-phase gastric emptying scintigraphy should be considered to exclude gastroparesis. This is particularly important because CNVS and gastroparesis can present with nearly identical symptoms, and the distinction rests on the demonstration (or absence) of objectively delayed gastric emptying.

The criterion specifies "likely to explain" symptoms, acknowledging that incidental findings (e.g., a small hiatal hernia, mild erythema on EGD without histologic inflammation) may be present but should not be assumed to account for the full clinical picture if they are not consistent with the severity and pattern of the patient's symptoms.

Criterion 4: Criteria Fulfilled for the Last 3 Months with Symptom Onset at Least 6 Months Before Diagnosis

This temporal criterion imposes two distinct requirements:

• Active symptom duration of 3 months: The specific symptom criteria (bothersome nausea at least 1 day/week and/or vomiting at least 1 episode/week) must have been continuously present for the most recent 3 months. This does not require that every single day or week within the 3-month period meets the threshold, but rather that the overall pattern is consistent with the frequency criterion when assessed over this timeframe.
• Total symptom duration of at least 6 months: The patient must have experienced nausea and/or vomiting symptoms (not necessarily at the diagnostic frequency threshold) for at least 6 months prior to the current evaluation. This criterion excludes patients with subacute or recent-onset nausea/vomiting, which are more likely to have an identifiable acute or subacute cause (e.g., medication initiation, viral illness, new-onset metabolic derangement).

The dual temporal requirement is particularly important in clinical practice because it guards against premature diagnosis. Patients with nausea and vomiting lasting less than 6 months should be managed with continued diagnostic vigilance, as organic causes may still declare themselves within this window.

Differentiating CNVS from Related Disorders

A structured approach to the differential diagnosis is critical in evaluating patients with chronic nausea and vomiting. CNVS shares overlapping features with several other conditions, and the distinctions have important implications for management.

Condition	Key Distinguishing Features
Gastroparesis	Objectively delayed gastric emptying on 4-hour scintigraphy (>10% retention at 4 hours). Symptoms overlap significantly with CNVS (nausea, vomiting, early satiety, bloating). The distinction rests on the gastric emptying study result. Some patients have borderline or fluctuating emptying rates, making classification challenging.
Cyclic vomiting syndrome (CVS)	Stereotypical, discrete episodes of intense nausea and vomiting lasting hours to days, separated by symptom-free intervals of weeks to months. In CNVS, symptoms are chronic and persistent (or nearly so), without the episodic, cyclical pattern of CVS. Some patients may transition between CNVS and CVS phenotypes over time.
Cannabinoid hyperemesis syndrome (CHS)	Recurrent episodes of severe nausea and vomiting in the setting of chronic, heavy cannabis use. Symptoms improve with prolonged cannabis cessation. Hot water bathing (compulsive bathing) is a classic but not universal feature. A thorough substance use history, including cannabis, is essential in any patient presenting with unexplained nausea and vomiting.
Functional dyspepsia	Postprandial fullness, early satiation, and epigastric pain or burning are the cardinal symptoms. Nausea may be present but is typically secondary to the dyspeptic symptoms rather than the dominant complaint. CNVS and functional dyspepsia frequently overlap, and Rome IV allows both diagnoses to coexist.
Gastroesophageal reflux disease (GERD)	Heartburn and acid regurgitation predominate. While nausea can occur in GERD, it is usually accompanied by typical reflux symptoms and often responds to acid suppression therapy. Upper endoscopy may show esophagitis.
Rumination syndrome	Effortless regurgitation of recently ingested food (within minutes of eating) without preceding nausea. The regurgitated food is rechewed or expelled. Does not occur during sleep. The mechanism is a conditioned abdominal compression, not true vomiting.
Bulimia nervosa	Self-induced vomiting in the context of binge eating, body image distortion, and compensatory behaviors. Vomiting is deliberate. Screening for eating disorders is a mandatory exclusion in the CNVS criteria.
Superior mesenteric artery (SMA) syndrome	Compression of the third portion of the duodenum by the SMA, causing postprandial nausea, vomiting, and abdominal pain. Typically seen in thin individuals after significant weight loss. CT angiography or upper GI series demonstrates the anatomical compression.
Central nervous system pathology	Elevated intracranial pressure (mass lesion, hydrocephalus, idiopathic intracranial hypertension), posterior fossa lesions, and Chiari malformation can all cause chronic nausea and vomiting. Headache, papilledema, and neurological deficits should prompt neuroimaging.
Medication-induced nausea	Numerous medications cause nausea and vomiting as a side effect (opioids, SSRIs, antibiotics, NSAIDs, metformin, chemotherapeutic agents). A thorough medication history, including over-the-counter and herbal supplements, is essential.

Clinical Evaluation and Diagnostic Approach

The diagnostic evaluation for suspected CNVS should proceed in a systematic, stepwise fashion. The goal is to confirm that the symptom pattern meets the Rome IV criteria while appropriately excluding organic, systemic, and metabolic causes.

Step 1: Detailed History

A thorough clinical history is the most important diagnostic tool. Key elements include:

• Symptom characterization: Onset, duration, frequency, and severity of nausea and vomiting; temporal relationship to meals; aggravating and relieving factors; presence or absence of associated symptoms (abdominal pain, bloating, early satiety, heartburn, weight loss, diarrhea)
• Dietary history: Dietary patterns, food triggers, avoidance behaviors, and caloric intake
• Medication history: All current medications, including over-the-counter agents, supplements, and herbal preparations; recent medication changes; known emetogenic agents
• Substance use: Specifically inquire about cannabis use (frequency, duration, and amount), alcohol, opioids, and other substances
• Eating disorder screening: Direct, non-judgmental questioning about body image, self-induced vomiting, binge eating, compensatory behaviors, and weight manipulation. Use of a validated screening instrument (e.g., SCOFF) is recommended.
• Psychosocial assessment: Screen for anxiety, depression, somatization, history of trauma or adverse life events, and current psychosocial stressors. Assess impact on quality of life, social functioning, and occupational performance.
• Prior evaluations: Document all previous diagnostic testing, specialist evaluations, and treatments attempted, including responses and side effects
• Red flag symptoms: Unintentional weight loss, GI bleeding (hematemesis, melena), progressive dysphagia, persistent abdominal pain, fever, new-onset headache with neurological symptoms, or symptoms of systemic illness

Step 2: Physical Examination

The physical examination in CNVS is often unremarkable but should be performed to screen for signs of organic disease, nutritional compromise, or complications of chronic vomiting:

• General appearance, body habitus, and nutritional status
• Vital signs, including orthostatic measurements if dehydration is suspected
• Abdominal examination for tenderness, distension, masses, organomegaly, or succussion splash (which may suggest gastric outlet obstruction or severely delayed emptying)
• Assessment for signs of dehydration (dry mucous membranes, skin turgor, capillary refill)
• Dental examination for enamel erosion (a sign of chronic acid exposure from vomiting)
• Inspection of the hands for Russell sign (calluses on the dorsal surface of the knuckles from self-induced vomiting)
• Thyroid examination
• Neurological screening (cranial nerves, fundoscopic examination for papilledema if CNS pathology is suspected)

Step 3: Laboratory Evaluation

Baseline laboratory studies should include:

• Complete blood count (CBC)
• Comprehensive metabolic panel (electrolytes, glucose, BUN, creatinine, hepatic function tests)
• Thyroid-stimulating hormone (TSH)
• Lipase
• Pregnancy test (in women of reproductive age)
• Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) if inflammatory disease is suspected
• Celiac serologies (tissue transglutaminase IgA with total IgA) if not previously tested
• Morning cortisol or cosyntropin stimulation test if adrenal insufficiency is considered

Step 4: Upper Endoscopy

Upper endoscopy (EGD) is explicitly required by the Rome IV criteria for CNVS. The procedure should include:

• Examination of the esophagus, stomach, and duodenum for mucosal pathology
• Standard biopsies of the esophagus (if reflux symptoms or dysphagia are present), stomach (to assess for Helicobacter pylori and chronic gastritis), and duodenum (to evaluate for celiac disease and eosinophilic duodenitis)
• Assessment for evidence of gastric outlet obstruction, pyloric stenosis, or mass lesions

Step 5: Gastric Emptying Study

A 4-hour solid-phase gastric emptying scintigraphy is strongly recommended (though not explicitly required by the Rome IV criteria) to differentiate CNVS from gastroparesis. The standardized protocol uses a technetium-99m-labeled egg meal and measures gastric retention at 1, 2, 3, and 4 hours. Delayed gastric emptying is defined as more than 10% retention at 4 hours. Because proton pump inhibitors, opioids, GLP-1 receptor agonists, and anticholinergic agents can slow gastric emptying, medication reconciliation and appropriate washout periods should be performed before the study.

Step 6: Additional Investigations (as Clinically Indicated)

Depending on the clinical picture, the following may be considered:

• Abdominal imaging: CT abdomen/pelvis or MRI to evaluate for structural abnormalities (SMA syndrome, malrotation, pancreatic or biliary pathology)
• Hepatobiliary iminodiacetic acid (HIDA) scan: If biliary dyskinesia is suspected (right upper quadrant pain, postprandial nausea associated with fatty foods)
• Brain MRI: If headache, papilledema, or neurological symptoms raise concern for central causes of nausea
• Autonomic testing: Tilt table testing, heart rate variability analysis, or thermoregulatory sweat testing if autonomic dysfunction is suspected
• Gastroduodenal manometry: Rarely needed but may be considered if a neuropathic or myopathic motility disorder is suspected

Treatment and Management

The management of CNVS is multimodal and should be tailored to the individual patient's symptom profile, severity, comorbidities, and psychosocial context. Because CNVS is a disorder of brain-gut interaction, effective management typically requires a combination of pharmacologic, behavioral, and dietary approaches.

Patient Education and the Therapeutic Relationship

Establishing a strong therapeutic relationship is foundational. Many CNVS patients have experienced diagnostic uncertainty, invalidation of their symptoms, and frustration with the healthcare system. The clinician should clearly explain the concept of a functional gastroduodenal disorder, frame the diagnosis positively (as a recognized, well-characterized condition, not a diagnosis of exclusion), and validate the patient's experience. Patients should understand that CNVS reflects altered brain-gut signaling rather than a "psychological" or "imagined" condition, and that effective treatments are available.

Dietary Modifications

Dietary interventions for CNVS are largely empiric and individualized, as no single dietary strategy has been proven in randomized trials. General recommendations include:

• Eating smaller, more frequent meals to reduce gastric distension
• Avoiding known trigger foods (commonly fatty, fried, or heavily spiced foods)
• Maintaining adequate hydration, especially in patients with frequent vomiting
• Minimizing carbonated beverages, which can exacerbate bloating and nausea
• Considering a low-fat diet, as fat delays gastric emptying and may potentiate nausea
• Avoiding prolonged fasting, which can worsen nausea through gastric acid accumulation

A registered dietitian should be involved in the care of patients with significant weight loss, nutritional deficiencies, or dietary restriction behaviors.

Pharmacologic Therapy

No medication is FDA-approved specifically for CNVS, and pharmacologic treatment is guided by clinical experience, expert consensus, and extrapolation from trials in related conditions. The following agents are commonly used:

Antiemetics

• Ondansetron: A 5-HT3 receptor antagonist that is widely used for nausea and vomiting. It is generally well tolerated and may be used on a scheduled or as-needed basis. Efficacy in chronic functional nausea is modest, and tachyphylaxis may occur with prolonged use.
• Promethazine: A first-generation antihistamine with antiemetic properties. Effective for acute nausea but limited by sedation and the risk of extrapyramidal side effects with chronic use.
• Prochlorperazine: A dopamine receptor antagonist used for nausea. Similar to promethazine, long-term use carries the risk of tardive dyskinesia and other extrapyramidal effects.
• Granisetron (transdermal): A transdermal 5-HT3 antagonist that provides sustained drug delivery and may be useful for patients who have difficulty with oral medications due to vomiting.

Neuromodulators

Neuromodulators (also termed gut-brain modulators) are increasingly recognized as central to the management of CNVS, particularly in patients with moderate to severe symptoms or significant psychosocial comorbidity:

• Tricyclic antidepressants (TCAs): Low-dose amitriptyline or nortriptyline (10-50 mg at bedtime) is one of the most commonly used and best-studied neuromodulators for functional GI disorders. TCAs modulate visceral pain and nausea pathways through their effects on serotonin and norepinephrine reuptake, as well as through anticholinergic, antihistaminic, and sodium channel-blocking properties. The NOVIN trial demonstrated efficacy of amitriptyline for functional dyspepsia, and clinical experience supports its use in CNVS. Side effects include dry mouth, constipation, drowsiness, and weight gain.
• Mirtazapine: A noradrenergic and specific serotonergic antidepressant (NaSSA) with potent 5-HT3 antagonist and antihistaminic activity. Mirtazapine has demonstrated antiemetic properties and is particularly useful in CNVS patients with comorbid weight loss, poor appetite, and insomnia, as it promotes weight gain and has sedating properties. Dosing is typically 7.5 to 30 mg at bedtime.
• Buspirone: A 5-HT1A partial agonist that enhances gastric accommodation (the ability of the fundus to relax and accept a meal). Small studies have shown that buspirone reduces postprandial nausea and improves symptoms in patients with impaired accommodation. Dosing is typically 5 to 15 mg three times daily.
• Olanzapine: An atypical antipsychotic with broad receptor antagonism (dopamine D2, serotonin 5-HT2, 5-HT3, histamine H1, muscarinic). Low-dose olanzapine (2.5-5 mg) has shown antiemetic efficacy in both chemotherapy-induced and chronic functional nausea settings. It may be considered for refractory cases. Metabolic side effects (weight gain, dyslipidemia, hyperglycemia) require monitoring.

Prokinetic Agents

• Metoclopramide: A dopamine D2 antagonist and weak 5-HT4 agonist with both prokinetic and antiemetic properties. Useful when mild gastric dysmotility coexists with CNVS. The FDA black box warning regarding tardive dyskinesia limits long-term use. Treatment should generally not exceed 12 weeks.
• Domperidone: A peripherally acting dopamine D2 antagonist with prokinetic and antiemetic effects. Available in some countries but not FDA-approved in the United States; may be obtained through the FDA expanded access program. Has a more favorable side-effect profile than metoclopramide regarding extrapyramidal effects but carries a risk of QTc prolongation.

Behavioral and Psychological Therapies

Given the prominent role of brain-gut interaction and psychosocial factors in CNVS, behavioral and psychological therapies are an integral part of management:

• Cognitive behavioral therapy (CBT): The most extensively studied psychological intervention for functional GI disorders. CBT for CNVS targets catastrophic thinking about nausea, avoidance behaviors, and maladaptive coping patterns. It can reduce nausea severity, improve coping, and decrease healthcare utilization. GI-specific CBT protocols have been developed and are available through specialized centers and online platforms.
• Gut-directed hypnotherapy: A specialized form of clinical hypnosis that uses suggestion to modulate gut sensation, autonomic function, and central processing of visceral signals. Randomized trials in functional dyspepsia and IBS have demonstrated sustained benefit, and emerging evidence supports its application in chronic nausea syndromes.
• Biofeedback and relaxation training: Techniques such as progressive muscle relaxation, diaphragmatic breathing, and heart rate variability biofeedback can reduce autonomic arousal and may diminish nausea intensity. These approaches are particularly useful in patients with comorbid anxiety.
• Acceptance and commitment therapy (ACT): A form of behavioral therapy that emphasizes psychological flexibility, acceptance of unpleasant sensations, and engagement in valued activities despite symptoms. ACT may be particularly relevant for CNVS patients who have developed significant functional impairment and avoidance behaviors.

Complementary and Integrative Approaches

• Ginger: Ginger (Zingiber officinale) has established antiemetic properties, mediated through 5-HT3 antagonism and direct effects on gastric motility. It is generally safe and may be tried as an adjunctive therapy. Available forms include ginger capsules (250 mg four times daily), ginger tea, and ginger chews.
• Acupuncture and acupressure: Stimulation of the P6 (Neiguan) acupoint on the volar wrist has been studied for various nausea conditions and may provide modest benefit in some patients. Wristband acupressure devices are commercially available and low-risk.
• Gastric electrical stimulation (GES): An implantable device that delivers high-frequency, low-energy electrical stimulation to the gastric wall. FDA-approved under a humanitarian device exemption for refractory gastroparesis, GES has also been used off-label in severe, medically refractory CNVS. The mechanism is thought to involve central antiemetic effects (modulation of vagal afferent signaling) rather than improvement in gastric emptying. Patient selection is critical, and the evidence base for CNVS specifically is limited.

Complications of Untreated or Refractory CNVS

Chronic nausea and vomiting, when persistent and inadequately managed, can lead to significant medical and psychosocial complications:

• Dehydration and electrolyte disturbances: Recurrent vomiting can cause hypokalemia, hypochloremic metabolic alkalosis, hypomagnesemia, and dehydration. Severe electrolyte abnormalities can lead to cardiac arrhythmias, muscle weakness, and renal dysfunction.
• Nutritional deficiencies and weight loss: Reduced oral intake due to nausea and caloric losses from vomiting can produce protein-calorie malnutrition, vitamin deficiencies (particularly B vitamins, iron, and fat-soluble vitamins), and significant weight loss.
• Dental erosion: Chronic exposure of the teeth to gastric acid during vomiting episodes can cause irreversible enamel erosion, dental caries, and dentinal hypersensitivity.
• Esophageal injury: Mallory-Weiss tears (mucosal lacerations at the gastroesophageal junction) can occur with forceful or repeated vomiting, presenting as hematemesis. Chronic acid exposure may also cause esophagitis.
• Impaired quality of life: CNVS significantly affects daily functioning, social participation, occupational productivity, and interpersonal relationships. Patients frequently report that chronic nausea, in particular, is a pervasive and debilitating symptom that colors every aspect of daily life.
• Psychological morbidity: Untreated CNVS is associated with worsening anxiety, depression, social isolation, and development of avoidance behaviors (e.g., fear of eating, avoidance of social meals, agoraphobia related to fear of vomiting in public).
• Healthcare overutilization: Patients with undiagnosed or poorly managed CNVS may experience repeated emergency department visits, hospitalizations, unnecessary surgical procedures, and escalating opioid or antiemetic use, all of which carry their own risks.

Overlap with Other Functional Gastrointestinal Disorders

The Rome IV framework explicitly recognizes that functional gastrointestinal disorders commonly co-occur. CNVS is no exception, and clinicians should be prepared to identify and manage overlapping conditions:

• Functional dyspepsia (FD): The most common overlap. Up to 50% of patients with chronic nausea also meet criteria for functional dyspepsia (postprandial distress syndrome and/or epigastric pain syndrome). Rome IV permits the coexistence of both diagnoses, and management should address both symptom domains.
• Irritable bowel syndrome (IBS): Nausea is a frequently reported symptom in IBS patients, and the overlap between CNVS and IBS is well documented. Shared pathophysiologic mechanisms (visceral hypersensitivity, central sensitization, altered gut-brain signaling) likely underlie this co-occurrence.
• Functional heartburn: Some CNVS patients also experience heartburn without evidence of acid reflux, consistent with functional heartburn. This overlap further supports the role of central sensitization in driving symptoms across multiple GI domains.
• Centrally mediated abdominal pain syndrome (CAPS): Previously known as functional abdominal pain syndrome, CAPS involves continuous or nearly continuous abdominal pain that is not fully explained by structural or metabolic disease. Patients with severe, refractory CNVS may have overlapping CAPS.

When multiple overlapping FGIDs are present, the treatment strategy should prioritize the most disabling symptom domain while selecting therapies (particularly neuromodulators and behavioral interventions) that have the potential to benefit multiple conditions simultaneously.

Special Considerations

CNVS and Cannabis Use

The relationship between cannabis use and chronic nausea/vomiting deserves special attention. Cannabis can both treat and cause nausea, depending on the pattern and duration of use. Cannabinoid hyperemesis syndrome (CHS) is characterized by episodic severe nausea and vomiting in the setting of chronic, heavy cannabis use, often with a compulsive hot bathing behavior. CHS must be excluded before a diagnosis of CNVS can be made in any patient who uses cannabis. This requires a candid discussion about cannabis use and, ideally, a trial of complete cannabis cessation for at least 2 to 4 weeks to assess whether symptoms improve. Urine drug screening may be helpful in cases where the history is uncertain.

CNVS in Adolescents and Young Adults

CNVS is increasingly recognized in adolescents and young adults, a population in which eating disorders, substance use, and psychosocial stressors are particularly prevalent. The diagnostic evaluation in this age group must include careful screening for eating disorders and cannabis use, as well as attention to the psychosocial context (academic stress, family dynamics, social media-related pressures). Early engagement of behavioral health providers is recommended.

Pregnancy and CNVS

Nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum (HG) are common and must be distinguished from a pre-existing or concurrent CNVS presentation. In patients with known CNVS who become pregnant, symptoms may worsen, improve, or remain unchanged. Management during pregnancy requires particular attention to medication safety, nutritional adequacy, and maternal-fetal well-being.

Refractory CNVS

A subset of patients with CNVS will have symptoms that are refractory to standard pharmacologic and behavioral interventions. In these cases, re-evaluation of the diagnosis is warranted (to ensure that organic causes have not been missed and that comorbid conditions are adequately treated). Management strategies for refractory cases may include:

• Combination neuromodulator therapy (e.g., a TCA plus mirtazapine, or a TCA plus olanzapine)
• Referral to a specialized neurogastroenterology or functional GI center
• Multidisciplinary pain and symptom management programs
• Consideration of gastric electrical stimulation in carefully selected patients
• Avoidance of chronic opioid use, which can worsen nausea through opioid-induced nausea and contribute to narcotic bowel syndrome

How This Calculator Works

This calculator applies the Rome IV diagnostic criteria for Chronic Nausea Vomiting Syndrome (CNVS) in a structured, stepwise format. The user evaluates whether each of the four required criteria is met based on the clinical history, examination, and results of prior investigations. All criteria must be fulfilled for a positive diagnosis. The output provides a clear determination of whether the Rome IV criteria are met and a detailed breakdown of each criterion.

This tool is intended for educational purposes and clinical decision support only. It does not replace clinical judgment, and all diagnostic and management decisions should be made by a qualified healthcare provider in the context of the individual patient.